Inhibition of IGF1R in Early MMTV-Wnt1 Mammary Tumors: A Transcriptomic Analysis

Joseph J Bulatowicz1, Alexander Lemenze2, Elvan Dogan1

  • 1Department of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling, Cancer Institute of New Jersey, New Jersey Medical School, Rutgers Health, Newark, NJ 07103, USA.

Cancers
|June 12, 2026
PubMed

Insights

Inhibiting the insulin-like growth factor 1 receptor (IGF1R) in mouse breast tumors revealed new KRT14+/KRT6A+ cells in metastases. These cells may serve as biomarkers for aggressive basal-like breast cancer with low IGF1R.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Insulin-like growth factor 1 receptor (IGF1R) dysregulation is linked to breast cancer initiation and progression.
  • The role of IGF1R underexpression in aggressive tumor phenotypes remains unclear.

Purpose of the Study:

  • To investigate the phenotypic and transcriptional consequences of IGF1R inhibition in MMTV-Wnt1 mouse mammary tumors.
  • To explore cellular heterogeneity and identify novel cell populations resulting from IGF1R blockade.

Main Methods:

  • Utilized a dominant-negative IGF1R to inhibit receptor activity in mouse mammary tumors.
  • Employed histopathological analysis and single-cell RNA-sequencing to assess tumor characteristics.
  • Correlated gene expression patterns in mouse models with human breast cancer patient data.

Main Results:

  • IGF1R inhibition did not significantly alter primary tumor architecture or differentiation markers.
  • Tumors with inhibited IGF1R exhibited metastatic lesions in the lungs.
  • Single-cell RNA-sequencing identified a novel KRT14+/KRT6A+ epithelial subpopulation in tumors and small lung metastases.
  • This subpopulation showed distinct transcriptional profiles and inverse correlation with IGF1R expression in human breast cancer.

Conclusions:

  • IGF1R inhibition in basal-like breast cancer models generates transcriptionally distinct KRT6a+/KRT14+ cells.
  • These cells are found in the smallest metastatic lesions, suggesting a role in early metastasis.
  • KRT14 and KRT6A expression may serve as potential biomarkers for metastatic capacity in low-IGF1R basal-like breast tumors.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...